Anna Steffen’s Post

View profile for Anna Steffen, graphic

Product Manager Clinical Marketing Strategy - Watchman EMEA bei Boston Scientific

Mark your calendar! The Option trial compares the safety and effectiveness of the WATCHMAN FLX device with oral anticoagulation for stroke prevention post-ablation. #LAAC #WatchmanFLX #BSCI

View organization page for Boston Scientific Cardiology, graphic

142,758 followers

We are excited to announce that results from the OPTION Clinical Trial have been accepted as a Late-Breaking Science Session at the 2024 AHA Conference! This pivotal study compares the safety and effectiveness of the WATCHMAN FLX™ #LAAC device with oral anticoagulation for stroke prevention post-ablation. Learn more about OPTION here: https://bit.ly/4drSpmE

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics